Edgar Filing: Tamir Biotechnology, Inc. - Form 4

Tamir Biotechnology, Inc. Form 4 April 30, 2010						
	STATES SECI	JRITIES AND EXCHANO	CF COMMISSION	OMB APPROVAL		
Check this box		Vashington, D.C. 20549		Number: 3235-0287		
Subject to Section 16. Form 4 or Form 5 Filed pur	rsuant to Section (a) of the Public	NGES IN BENEFICIAL SECURITIES 16(a) of the Securities Excl Utility Holding Company A	nange Act of 1934, ct of 1935 or Sectio	Expires: 2005 Estimated average burden hours per response 0.5		
See Instruction 1(b).	30(h) of the 3	Investment Company Act of	f 1940			
(Print or Type Responses)						
1. Name and Address of Reporting BRANCACCIO JOHN P	Symbol	uer Name and Ticker or Trading 1 r Biotechnology, Inc. [ACEI	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) (First) (I		of Earliest Transaction				
C/O TAMIR BIOTECHNOL INC., 300 ATRIUM DRIVE	LOGY, 04/28/	n/Day/Year) /2010	X_ Director Officer (give below)	title Other (specify below)		
(Street) SOMERSET, NJ 08873		mendment, Date Original /onth/Day/Year)	Applicable Line) _X_ Form filed by 0	Dint/Group Filing(Check Dne Reporting Person More than One Reporting		
	(Zin)		Person			
(City) (State)		able I - Non-Derivative Securities		-		
1.Title of Security (Instr. 3)2. Transaction Date (Month/Day/Year)	Execution Date, if any	3.4. SecuritiesTransactionAcquired (A) orCodeDisposed of (D)(Instr. 8)(Instr. 3, 4 and 5)	Securities H Beneficially (Owned (Following (5. Ownership7. Nature ofForm: DirectIndirectD) or IndirectBeneficialI)OwnershipInstr. 4)(Instr. 4)		
		(A) or Code V Amount (D) Prio	Reported Transaction(s) (Instr. 3 and 4)			
Reminder: Report on a separate line	e for each class of se	•				
		information co required to res	respond to the collect ontained in this form spond unless the form rently valid OMB con	are not (9-02) m		

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)

Edgar Filing: Tamir Biotechnology, Inc. - Form 4

(Instr. 3)	Price of Derivative Security	(Month/Day	y/Year)	(Instr. 8	Disp	Disposed of (D) (Instr. 3, 4, and					
				Code	V ((A)	(D)	Date Exercisable	Expiration Date	Title	Amount Number Shares
Common Stock (Right to Buy) <u>(1)</u>	\$ 0.26	04/28/2010		A	125	5,000		12/31/2010	12/31/2015	Common Stock	125,00

Reporting Owners

Reporting Owner Name / Address

Relationships

Х

Director 10% Owner Officer Other

BRANCACCIO JOHN P C/O TAMIR BIOTECHNOLOGY, INC. 300 ATRIUM DRIVE SOMERSET, NJ 08873

Signatures

/s/ John Brancaccio 04/29/2010 **Signature of Date Reporting Person

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Issued under the Company's 2004 Stock Incentive Plan and qualified under Rule 16b-3(d).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.